Annual report [Section 13 and 15(d), not S-K Item 405]

Consolidated Statements of Operations

v3.25.0.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Nov. 30, 2024
Nov. 30, 2023
Revenue $ 31,986,106 $ 31,343,695
Costs and Expenses:    
Cost of sales 7,947,752 8,390,463
Selling, general and administrative expenses 18,521,218 17,167,361
Impairment of public inventory 0 3,737,133
Impairment of Duke assets 0 13,108,064
Change in fair value of contingent consideration 2,794 (1,050,978)
Research, development and related engineering 1,242,536 1,171,456
Depreciation and amortization 483,522 1,124,228
Total costs and expenses 28,505,822 43,647,727
Operating Income (Loss) 3,480,284 (12,304,032)
Other Income (Expense):    
Gains on marketable securities 1,076,051 50,777
Gain on interest rate swap 105,887 122,113
Other income 6,583 3,441
Interest expense (1,864,684) (1,236,794)
Total other income (expense) (676,163) (1,060,463)
Income before income tax expense 2,804,121 (13,364,495)
Income tax (expense) benefit (2,402,026) 3,842,826
Net income (loss) $ 402,095 $ (9,521,669)
Net income (loss) per common share - basic $ 0.05 $ (1.14)
Weighted average common shares outstanding - basic 8,130,676 8,340,839
Net income (loss) per common share - diluted $ 0.05 $ (1.14)
Weighted average common shares outstanding - diluted 8,212,510 8,340,839
Tianhe Stem Cell Biotechnologies Inc [Member]    
Costs and Expenses:    
Impairment of investment $ 308,000 $ 0
Processing and Storage Fees [Member]    
Revenue 31,551,550 30,796,091
Public Banking [Member]    
Revenue 366,672 481,148
Product [Member]    
Revenue $ 67,884 $ 66,456